Pegylated Interferon Lambda w/wo Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
-
Investigator: Mandana Khalili, MD
Sponsor: Bristol-Myers Squibb Company
Location(s): South Korea; Japan; India; Singapore; Belgium; Finland; France; Greece; Italy; Netherlands; Russia; United Kingdom; Mexico; Argentina; Brazil; Chile; Canada; Australia; New Zealand
Description
The purpose of this study is to determine if 24 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and 12 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and Daclatasvir will be safe and effective for treatment of hepatitis C compared to 24 weeks of treatment with Pegylated Interferon Alfa-2a plus Ribavirin.